Fisher & Paykel Healthcare Corporation (ASX: FPH) is an Australian-listed company in the Healthcare sector with a market capitalisation of $19.25B and the 43rd-largest security on the ASX by market capitalisation. The FPH share price is $32.77, up 2.31% today and down 2.76% over the past 12 months. Shares have traded between $26.51 and $35.31 over the past 52 weeks. FPH trades on a price-to-earnings ratio of 21.24, above the Healthcare sector median of 10.89, and pays a trailing dividend yield of 0.51%. In its most recent reported period (ending 31 Mar 2026), Fisher & Paykel Healthcare Corporation reported revenue of $1.25B and a net profit of $257.4M (20.6% margin).
About Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited, operating with its various subsidiaries, is a global innovator in medical device technology. The company specializes in the design, production, and worldwide distribution of sophisticated products and systems. These solutions primarily cater to acute and chronic respiratory care, support during surgical procedures, and the treatment of obstructive sleep apnea (OSA) in both clinical settings and home environments. Their product lineup includes notable items such as the Airvo 2, a humidified nasal high flow system; Optiflow, designed for nasal high flow therapy; and the F&P 850 System, which offers both non-invasive and invasive ventilation capabilities. For infant care, the company supplies respiratory products used in resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Hospital-grade offerings comprise humidification devices, breathing circuits, chambers, diverse masks, nasal cannulas, surgical accessories, and various interfaces. For homecare users, Fisher & Paykel provides masks, CPAP devices, data management software, humidifiers, and complementary accessories. Established in 1934, the company maintains its headquarters in Auckland, New Zealand.
